General
Preferred name
ETRIPAMIL
Synonyms
MSP-2017 ()
(-)-MSP-2017 ()
MS)-MSP-2017 ()
Etripamilo ()
P&D ID
PD058527
CAS
1593673-23-4
Tags
available
drug candidate
Drug Status
investigational
Max Phase
3.0
Drug indication
Atrial fibrillation
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 268
DESCRIPTION Etripamil, a benzoates derivative, has been found to be a calcium channel antagonist that could be used against hypertension and arrhythmic. It is currently under Phase II trail against paroxysmal supraventricular tachycardia. (BOC Sciences Bioactive Compounds)
DESCRIPTION Etripamil (MSP-2017) displays atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells. Etripamil is an antagonist of short-acting L-type calcium-channel. It has a rapid onset of action designed for intranasal administration. It is also used to treat Paroxysmal Supraventricular Tachycardia. (TargetMol Bioactive Compound Library)
Compound Sets
6
BOC Sciences Bioactive Compounds
etripamil-cas-1593673-23-4-item-475886
ChEMBL Drugs
CHEMBL3707312
DrugBank
DB12605
MedChem Express Bioactive Compound Library
HY-17611
ReFrame library
TargetMol Bioactive Compound Library
T15257
External IDs
15
Properties
(calculated by RDKit )
Molecular Weight
452.27
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
12
Ring Count
2
Aromatic Ring Count
2
cLogP
4.86
TPSA
71.79
Fraction CSP3
0.48
Chiral centers
1.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Calcium Channel
L-type calcium channel
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Metabolism
Source data